VMVelázquez-Hernández María-Elena

Velázquez-Hernández María-Elena

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Velázquez-Hernández María-Elena has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adverse events and potential herb-drug interactions of plants used for psoriasis: A systematic review

    by Marwan Gagaa, Roberto Esquivel-García, María E. Velázquez-Hernández, Isis B. Bermúdez-Camps, Manuel García-Pérez, Alain R. Rodríguez-Orozco, Ivette Reyes-Hernández, Martha E. García-Pérez

    Context: Medicinal plants have been widely used for psoriasis management for centuries. However, their safety profiles remain insufficiently documented. Aims: To systematically evaluate adverse events (AEs) and potential pharmacokinetic interactions of antipsoriatic herbal treatments. Methods: A PRISMA-compliant review was conducted using PubMed, Cochrane, Google Scholar, Web of Science, and Scopus databases (January 2015-December 2022). Clinical trials, case reports, and ethnomedicinal studies reporting AEs of single plant antipsoriatic preparations were included. CONSORT criteria for herbal medicines were applied to assess study quality. Results: Eleven studies covering nine herbal treatments were included. While most of reported AEs were mild, severe cases involving Indigo naturalis, Psoralea corylifolia, and Ranunculus arvensis were documented. Several herbal metabolites (indirubin, psoralen, curcumin, triptolide) showed potential pharmacokinetic interactions with conventional drugs. Conclusions: While generally well tolerated, antipsoriatic herbal therapies can induce mild to severe AEs and may alter drug metabolism. Long-term, high-quality randomized trials are needed to establish their safety profile.

  • Small molecules under development for psoriasis: on the road to the individualized therapies

    by Cervantes-Durán Claudia, Velázquez-Hernández María-Elena, Valentín-Escalera Josué, Bartolomé-Camacho María-Carmen, Rodríguez-Orozco Alain-Raimundo, García-Pérez Martha-Estrella

    Psoriasis is an incurable cutaneous illness characterized by the presence of well-delimited reddish plaques and silvery-white dry scales. So far, there is a limited understanding of its pathogenesis, though recent discoveries on the immunological, genetic and molecular aspects of this disease have significantly contributed to the identification of new targets and the development of novel drugs. Despite these advances, many patients are still dissatisfied, so to improve patient satisfaction, reliability, and clinical outcomes, the individualization of the treatments for this disease becomes a necessity. This review summarizes recent findings related to psoriasis pathogenesis and describes new small molecules and targets recently identified as promising for treatments. Additionally, the current status, challenges and the future directions for achieving individualized therapy for this disease and the need for more collaborative studies are discussed. The individualization of treatments for psoriasis, rather than a goal, is analyzed as a process where a dynamic integration between the needs and characteristics of the patients, the pharmacological progress, and the clinical decisions takes place.